Articles from Eradivir Inc.

Eradivir Inc., the leading clinical-stage biotech company developing antibody recruiting small molecules to treat disease, today announced EV148 as its development candidate for the treatment of Respiratory Syncytial Virus (RSV). The company is presenting its best-in-class pre-clinical efficacy findings in an oral presentation at RSVVW on February 19, 2026.

Eradivir Inc., a clinical-stage biotechnology company that targets the power of the immune system to treat disease, today announced the successful completion of its Phase 2a clinical trial for EV25, a therapy for the treatment of influenza. The study demonstrated that EV25 is safe, well-tolerated and significantly reduces viral loads and influenza symptoms, paving the way for a larger Phase 2b trial.

Eradivir Inc., a clinical-stage biotechnology company that harnesses the power of the immune system to target and treat disease, today announced the recent closing of a $10 million private financing round. The investment will support continued clinical development of the company’s lead antiviral therapeutic for influenza, EV25, and advancement of a second molecule, EV148, for the treatment of respiratory syncytial virus (RSV).

Eradivir Inc., a clinical-stage biotechnology company that harnesses the power of the immune system to target and treat disease, today announced it will present at the Biotechnology Innovation Organization (BIO) International Convention taking place in Boston, Mass., on Tuesday, June 17, 2025, beginning at 4 p.m. in room 153A.